Takeda chooses US base for its global development headquarters
pharmafile | April 2, 2009 | News story | Research and Development |Â Â TakedaÂ
Takeda Pharmaceutical Company is shifting its global development HQ from Japan to the US.
The move will see that function up sticks from Osaka to Deerfield, Illinois and is expected to be completed by July this year.
The company, whose products include asthma drug Bronica, hypertension treatment Blopress and diabetes brand Actos, already has regional hubs in Japan, the US, Europe and Asia.
At the same time, the company has restructured its management team, creating three new senior positions this week in a bid to bolster its global business.
Shigenori Ohkawa, general manager of the company's pharmaceutical research division, has become chief scientific officer.
In charge of global research, development, chemistry manufacturing and controls (CMC) and intellectual property, Ohkawa will be expected to travel between the US and Japan.
Hiroyuki Odaka, director of Takeda's main pharmacology research laboratory, will replace Ohkawa.
Meanwhile Alan MacKenzie has been made executive vice president, international operations, and will be based in the US.
He is responsible for commercial operations in the US, Europe and Asia, as well as global medical affairs and international marketing.
MacKenzie was formerly president and chief executive of Takeda Pharmaceuticals North America and will be replaced by Shinji Honda, general manager of the overseas business planning department.
That department will be dissolved on May 1. Both the newly-created roles will sit in a new wholly-owned affiliate, Takeda Pharmaceuticals International.
To complete the restructure, the post of chief administrative officer will also be established, although it has not yet been filled. The role will lead on issues of human resources, finance, accounting, legal and corporate communications across the company.
All report to company president Yasuchika Hasegawa, who said the restructure is aimed at simplifying decision making, promoting collaboration between departments and strengthening the company's global operations.
In other changes, Tetsuo Miwa will become general manager of the company's CMC Centre and Nancy Joseph-Ridge will replace Masaomi Miyamoto as general manager of Takeda's pharmaceutical development division.
Yoichi Okumura, general manager of the intellectual property department, and Erich Brunn, chief executive of Takeda Pharmaceuticals Europe, will stay in their posts.
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
